dr. kahl discusses unmet needs in mcl
Published 5 years ago • 74 plays • Length 0:57Download video MP4
Download video MP3
Similar videos
-
1:32
dr. kahl on findings from the l-mind study with tafasitamab in dlbcl
-
1:07
dr. kahl discusses the potential of frontline ibrutinib in mcl
-
2:19
dr. kahl discusses polatuzumab vedotin in lymphoma
-
0:56
dr. kahl on the potential of car t-cell therapy in mcl
-
2:03
dr. kahl on considerations for treatment strategies in cll
-
11:52
how much money do you need to start an iul policy? what is the minimum and/or maximum?
-
10:12
what's the minimum amount you can invest in a tax-free iul?
-
10:04
mantle cell lymphoma for newly diagnosed patients
-
4:06
identifying unmet needs in relapsed/refractory mcl
-
1:33
dr. kahl on the utility of tafasitamab/lenalidomide in dlbcl
-
1:02
brad s. kahl, md, considers the unmet medical needs in treatment of hodgkin lymphoma
-
1:25
dr. kahl on remaining challenges in indolent non-hodgkin lymphoma
-
1:17
dr. kahl on treatment strategies for indolent lymphoma
-
4:07
author voices: brad kahl, md
-
1:07
exploring unmet needs and btk inhibitors in the mcl population
-
1:49
dr. kahl discusses the construction of adcs for lymphoma treatment
-
4:54
options for upfront therapy in mcl
-
1:53
dr. kahl on frontline btk inhibitor selection in cll
-
1:34
unmet needs in t-cell lymphoma
-
1:41
dr. smith on frontline treatment options in mcl
-
1:31
a short discussion of the unmet needs of cll patients
-
1:05
dr. kahl on the current treatment landscape in relapsed/refractory inhl